Halozyme Therapeutics Inc (NAS:HALO)
$ 48.13 0.1 (0.21%) Market Cap: 6.12 Bil Enterprise Value: 6.95 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 87/100

Halozyme Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 05:40PM GMT
Release Date Price: $15.46 (+0.26%)
Graig Suvannavejh
Goldman Sachs Group Inc., Research Division - Executive Director & Senior Equity Research Analyst

Okay. I think it's about 10:40, so why don't we get started with the next session? By introduction, my name is Graig Suvannavejh. I'm on the biotech research team here at Goldman Sachs. But before I introduce our next guest and speaker, there are some disclaimers that I am obligated to read, so please bear with me.

We are required to make certain disclosures and public appearances about Goldman Sachs' relationships with companies that are being discussed. Disclosures relate to investment banking relationships, compensation received or 1% or more ownership. We are prepared to read aloud disclosures for any issuer upon request. However, these disclosures are available on our most recent reports available to U.S. clients on our firm's portal.

Lastly, the views stated by non-Goldman Sachs personnel do not necessarily reflect those of Goldman Sachs.

So with that, I want to welcome Halozyme CEO, Helen Torley. Welcome. And in the audience, we also have Vice

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot